Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We found that SHP2i treatment depleted alveolar and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Kwan Ho, Li, Shuai, Khodadadi-Jamayran, Alireza, Jen, Jayu, Han, Han, Guidry, Kayla, Chen, Ting, Hao, Yuan, Fedele, Carmine, Zebala, John A., Maeda, Dean Y., Christensen, James G., Olson, Peter, Athanas, Argus, Loomis, Cynthia A., Tsirigos, Aristotelis, Wong, Kwok-Kin, Neel, Benjamin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758507/
https://www.ncbi.nlm.nih.gov/pubmed/34353854
http://dx.doi.org/10.1158/2159-8290.CD-21-0369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758507/
https://www.ncbi.nlm.nih.gov/pubmed/34353854
http://dx.doi.org/10.1158/2159-8290.CD-21-0369

Ejemplares similares